Literature DB >> 24698522

A boronate-linked linear-hyperbranched polymeric nanovehicle for pH-dependent tumor-targeted drug delivery.

Hui-zhen Jia1, Jun-yi Zhu2, Xu-li Wang3, Han Cheng1, Gang Chen2, Yi-fang Zhao2, Xuan Zeng1, Jun Feng4, Xian-zheng Zhang1, Ren-xi Zhuo1.   

Abstract

Advanced drug delivery systems, which possess post-functionalization feasibility to achieve targetability and traceability, favorable pharmacokinetics with dynamic but controllable stability, and preferable tumor accumulation with prolonged drug residence in disease sites, represent ideal nanomedicine paradigm for tumor therapy. To address this challenge, here we reported a dynamic module-assembly strategy based on reversible boronic acid/1,3-diol bioorthogonality. As a prototype, metastable hybrid nanoself-assembly between hydrophobic hyperbranched diol-enriched polycarbonate (HP-OH) and hydrophilic linear PEG terminated with phenylboronic acid (mPEG-PBA) is demonstrated in vitro and in vivo. The nanoconstruction maintained excellent stability with little leakage of loaded drugs under the simulated physiological conditions. Such a stable nanostructure enabled the effective in vivo tumor accumulation in tumor site as revealed by NIR imaging technique. More importantly, this nanoconstruction presented a pH-labile destruction profile in response to acidic microenvironment and simultaneously the fast liberation of loaded drugs. Accordingly at the cellular level, the intracellular structural dissociation was also proved in terms of the strong acidity in late endosome/lysosome, thus favoring the prolonged retention of remaining drug-loaded HP-OH aggregates within tumor cells. Hence, our delicate design open up a dynamical module-assembly path to develop site and time dual-controlled nanotherapeutics for tumor chemotherapy, allowing enhanced tumor selectivity through prolonged retention of delivery system in tumor cells followed by a timely drug release pattern.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Boronate linkage; Dual-controlled drug delivery; Nanoassembly; Passive tumor targeting; pH-sensitivity

Mesh:

Substances:

Year:  2014        PMID: 24698522     DOI: 10.1016/j.biomaterials.2014.03.029

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

Review 1.  Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.

Authors:  Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas
Journal:  Adv Healthc Mater       Date:  2021-05-11       Impact factor: 11.092

2.  GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.

Authors:  Glen P Marszalowicz; Adam E Snook; Michael S Magee; Dante Merlino; Lisa D Berman-Booty; Scott A Waldman
Journal:  Oncotarget       Date:  2014-10-15

3.  In Vitro Studies of Polyhedral Oligo Silsesquioxanes: Evidence for Their Low Cytotoxicity.

Authors:  Anna Janaszewska; Kinga Gradzinska; Monika Marcinkowska; Barbara Klajnert-Maculewicz; Wlodzimierz A Stanczyk
Journal:  Materials (Basel)       Date:  2015-09-10       Impact factor: 3.623

4.  Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy.

Authors:  Liang Ge; Xinru You; Jun Huang; Yuejian Chen; Li Chen; Ying Zhu; Yuan Zhang; Xiqiang Liu; Jun Wu; Qian Hai
Journal:  Front Pharmacol       Date:  2018-06-12       Impact factor: 5.810

Review 5.  Dendritic Polymers for Theranostics.

Authors:  Yuan Ma; Quanbing Mou; Dali Wang; Xinyuan Zhu; Deyue Yan
Journal:  Theranostics       Date:  2016-04-27       Impact factor: 11.556

6.  Recent progress on nanoparticle-based drug delivery systems for cancer therapy.

Authors:  Yanru Xin; Mingming Yin; Liyuan Zhao; Fanling Meng; Liang Luo
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

Review 7.  Fe₃O₄ Nanoparticles in Targeted Drug/Gene Delivery Systems.

Authors:  Lazhen Shen; Bei Li; Yongsheng Qiao
Journal:  Materials (Basel)       Date:  2018-02-23       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.